Navigation Links
Silymarin does not affect virus activity or ALT levels in
Date:2/1/2008

ological response in only a third to a half of all patients with the predominant form of the infection in the U.S., namely genotype 1, and it can cause unpleasant and sometimes serious side effects. The NIH study, referred to as the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial, was designed, therefore, to treat persons with advanced chronic hepatitis C who had failed previous antiviral therapy with the hope that the long-term treatment would reduce progression of the chronic liver disease even if it did not affect the virus itself. The reason for interviewing enrollees in the trial was to determine the extent of use of alternative therapies in this committed group, since the popularity of herbal products has increased in the U.S., many HCV patients choosing to supplement, or even replace, the standard treatment with herbals. Silymarin (milk thistle extract) has been the most popular option for people with liver disease. Although it is the most frequent product utilized, silymarin has not been rigorously studied using accepted scientific approaches, and therefore such studies are clearly required and warranted.

For the present survey, researchers interviewed all HALT-C participants on past and current use of all prescription and non-prescription drugs, including herbal medications, dietary supplements and other botanical products. Of 1145 study participants, 56 percent said that they had never used herbal products, while 23 percent were using them currently, some 60 different varieties. Silymarin was by far the most common. Usage was higher among men, among non-Hispanic whites, and among the more highly educated. Interestingly, the researchers also found geographic disparities in silymarin usage. It was most popular in Colorado, Michigan and Southern California and least popular in Maryland and Massachusetts.

In comparing the clinical data of silymarin users and non-users, the researchers found that the levels of HCV
'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Cutting Salt Wont Affect Foods Safety
2. A childs IQ could be affected by maternal epilepsy
3. Sexual function affected by stem cell transplant according to long-term study
4. Family history of alcoholism affects response to drug used to treat heavy drinking
5. Obesity Wont Affect Seniors Memory
6. Genetic variation affects smoking cessation treatment
7. Schizophrenia candidate genes affect even healthy individuals
8. R rating might be unlikely to affect teens exposure to smoking in movies
9. Painful condition affecting kidney failure patients increases risk of death
10. Patients perceived cancer care unaffected by lower Medicare reimbursements
11. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... This Fourth of July, Peacock ... Alley story including hard work, tenacity, perseverance, commitment to quality, honesty and love of ... Born of Mary Ella Gabler's simple love of quilts, Peacock Alley was fully realized ...
(Date:6/29/2015)... ... 2015 , ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame ... natural skincare and even culinary uses, was especially designed for Oil Pulling. , ... Oil Pulling can accomplish this. Oil Pulling is an Ayurvedic practice that is easy ...
(Date:6/29/2015)... ... June 30, 2015 , ... With thousands of children in ... in a much-needed autism support center, planned at Utah Valley University, in Orem, Utah. ... for the center and the building in which it will be housed. , Utah ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one ... Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons ...
(Date:6/29/2015)... ... 29, 2015 , ... The Society for Immunotherapy of Cancer ... granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of metastatic ... of nivolumab for patients with metastatic melanoma in Europe represents a major advance ...
Breaking Medicine News(10 mins):Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3
... ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), announced ... (NDA) to the U.S. Food and Drug Administration ... approval for Xibrom QD,as a treatment for inflammation, ... ophthalmic solution), Xibrom is a topical non-steroidal ...
... Will Fund 20 Percent of Cost for New Hospital, ... that it has reached its $50 million Capital Campaign,goal, ... ever,undertaken. A recent gift of $500,000 from the Stephen ... (Photo: http://www.newscom.com/cgi-bin/prnh/20071220/DC10448 ), "It,s only ...
... 20 Today URAC called for,comments on ... Health Web,Site, HIPAA Privacy (Business Associate and ... Covered Entity) accreditation programs.,URAC is seeking input ... care management organizations and health plans. The,deadline ...
... MCG Capital,Corporation (Nasdaq: MCGC ) today announced ... the acquisition of Gould & Lamb, LLC by ABRY,Partners ... company that is unique to,the workers, compensation industry. The ... workers, compensation industry,since 2001. Having completed in excess of ...
... ... Nataline Sarkisyan ... GLENDALE, Calif., Dec. 20 In a stunning turn around,insurance ... California Nurses Association/National Nurses Organizing Committee,helped to generate, and agreed ...
... of Howard G. Smith,announces a September 4, 2007, ... in,the securities class action lawsuit filed on behalf ... Pharmaceuticals, Inc. ("Threshold,Pharmaceuticals" or the "Company")(Nasdaq: THLD ... (the "Class Period"), including purchasers in Threshold,s,February 4, ...
Cached Medicine News:Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:MCG Capital Invests in Gould & Lamb 2Health News:CIGNA Capitulates to Patient Revolt 2Health News:CIGNA Capitulates to Patient Revolt 3Health News:Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc. 2
(Date:6/29/2015)... 29, 2015 The Parenteral Drug Association is ... Board of Professional Engineers and Land Surveyors ... to professional engineers for continuing professional competency (CPC) credits. ... value and quality of PDA,s professional education offerings," said ... and hands-on professional training at the Training and Research ...
(Date:6/29/2015)... , June 29, 2015  VisionCare Ophthalmic ... visual prosthetic devices for the treatment of ... publication of "Long-Term (60-month) Results for the ... Stratified by Age in Patients with End-Stage ... . The 5-year data show substantial retention ...
(Date:6/29/2015)... June 29, 2015 Dermatological drugs ... revenues ,Where is the market for dermatological drugs heading? ... Visiongain ,s new report shows you potential revenues and ... Our 310 page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 2Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 3Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 4Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8
... at the 2011 Pharmaceutical Care Management Association (PCMA),s ... President and CEO Eric Elliott speak about the ... managers as health care reform is implemented, industry ... the market and the pipeline of new treatments ...
... DALLAS, Feb. 8, 2011 ... known for its expertise in understanding consumer data, translating ... effective creative with measurable results, today announced that Peter ... Strategy - Healthcare.  Dannenfelser, a pharmaceutical marketing executive with ...
Cached Medicine Technology:Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 3
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: